o-National Taiwan University Hospital-peptic ulcer

o-National Taiwan University Hospital-peptic ulcer refers to a Phase 3 randomized clinical trial (NCT01182597) evaluating the comparative efficacy of two proton pump inhibitors (PPIs) for the prevention of rebleeding in patients with high-risk peptic ulcers. The study, led by National Taiwan University Hospital, compared oral lansoprazole (Takepron OD) at 30mg every 12 hours to intravenous pantoprazole (Pantoloc) administered as a 3.3mg/hr infusion for 72 hours following successful endoscopic hemostasis. Both medications function by covalently binding to and inhibiting the H+/K+-ATPase enzyme (the proton pump) in gastric parietal cells, which is the final step in gastric acid secretion. The trial's primary objective was to determine if oral PPI therapy could serve as an effective, lower-cost alternative to intravenous administration in this high-risk patient population.

Brand names

Takepron ODPantoloc

Other names

Oral Versus Intravenous Proton Pump Inhibitor Treatment in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis